Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Subgroup analyses from the randomized, Phase 3 VERONA study of venetoclax with azacitidine (Ven+Aza) versus placebo with azacitidine (Pbo+Aza) in patients with treatment-naïve, intermediate and higher-risk Myelodysplastic Syndromes (HR MDS)

View Full Paper
Ask AI
Bookmark
Share

Authors

GGGuillermo Garcia‐ManeroPFPierre FenauxMHMarek Hus

Discussion

Loading...

Member takes

Overview

Randomized trial reports modified overall response with venetoclax in treatment-naïve patients with HR MDS, suggesting enhanced efficacy compared to placebo.

Key Points

  • Modified overall response was significantly higher with venetoclax plus azacitidine compared to placebo plus azacitidine.
  • Efficacy analysis included 509 patients, with a median age of 72 years and well-balanced baseline characteristics.
  • Observational analysis revealed trends favoring venetoclax in younger patients and those with TP53 mutations.
  • These findings may enable tailored treatment approaches for patients with hematologic malignancies.

Cite This Study

Garcia‐Manero et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc6chttps://doi.org/10.1182/blood-2025-235
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Results from paradigm - a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia2025 · 33 citations
  2. 2Phase II study of clinical efficacy of venetoclax in combination with azacitidine in patients with therapy related myelodysplastic syndrome (t-MDS)2025
  3. 3Venetoclax and azacytidine in childhood primary advanced myelodysplastic syndromes, refractory/relapsed Acute Myeloid Leukemia and therapy-related myeloid diseases2025
  4. 4Outcomes of patients (pts) with higher-risk myelodysplastic syndromes (HR-MDS) treated with hypomethylating agents (HMA) + venetoclax (VEN) – a large analysis from the international consortium for MDS (icMDS) validate database2025
  5. 5The role of hypomethylating agents and venetoclax combination in higher risk myelodysplastic syndromes2025